Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | APAF1 | O14727 | 1/20 | 0.65 |
| ▸ | RECQL | P46063 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | MPO | P05164 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | BLM | P54132 | 1/20 | 0.65 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.65 |
| ▸ | DNMT1 | P26358 | 3/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL828692 | 1.00 | SMN1; SMN2 (0.67) | SMN1; SMN2KDM4EMAPTKMT2AMEN1 | |
| SCHEMBL31414630 | 0.89 | SMN1; SMN2 (0.63) | SMN1; SMN2KDM4EMAPTKMT2AMEN1 | |
| SCHEMBL1162356 | 0.87 | SMN1; SMN2 (0.65) | SMN1; SMN2KDM4EMAPTKMT2AMEN1 | |
| SCHEMBL6843791 | 0.87 | SMN1; SMN2 (0.65) | SMN1; SMN2KDM4EMAPTKMT2AMEN1 | |
| SCHEMBL6843792 | 0.87 | SMN1; SMN2 (0.65) | SMN1; SMN2KDM4EMAPTKMT2AMEN1 | |
| SCHEMBL3855611 | 0.87 | KDM4E (0.68) | SMN1; SMN2KDM4EMAPTKMT2AMEN1 | |
| SCHEMBL3380280 | 0.87 | SMN1; SMN2 (0.65) | SMN1; SMN2KDM4EMAPTKMT2AMEN1 | |
| SCHEMBL3380277 | 0.87 | SMN1; SMN2 (0.65) | SMN1; SMN2KDM4EMAPTKMT2AMEN1 | |
| SCHEMBL1162357 | 0.87 | SMN1; SMN2 (0.65) | SMN1; SMN2KDM4EMAPTKMT2AMEN1 | |
| SCHEMBL3378235 | 0.87 | SMN1; SMN2 (0.65) | SMN1; SMN2KDM4EMAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201947-A1 | OXIDIZED PARAOXONASE 1 AND PARAOXONASE 1/HDL PARTICLE NUMBER RATIO AS RISK MARKERS FOR CARDIOVASCULAR DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2011-08-18 | — | — | US | claimed |
| EP-2268305-A2 | OXIDIZED PARAOXONASE 1 AND PARAOXONASE 1/HDL PARTICLE NUMBER RATIO AS RISK MARKERS FOR CARDIOVASCULAR DISEASE | The Cleveland Clinic Foundation (US) | 2011-01-05 | — | — | EP | claimed |
| WO-2009114875-A2 | OXIDIZED PARAOXONASE 1 AND PARAOXONASE 1/HDL PARTICLE NUMBER RATIO AS RISK MARKERS FOR CARDIOVASCULAR DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2009-09-17 | — | — | WO | claimed |
| US-20250289868-A1 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | REGENERON PHARMA (US) | 2025-09-18 | — | — | US | disclosed |
| US-12338274-B2 | Anti-VEGF protein compositions and methods for producing the same | REGENERON PHARMACEUTICALS, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250197474-A1 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | REGENERON PHARMACEUTICALS, INC. | 2025-06-19 | — | — | US | disclosed |
| US-12319728-B2 | Anti-VEGF protein compositions and methods for producing the same | REGENERON PHARMACEUTICALS, INC. (US) | 2025-06-03 | — | — | US | disclosed |
| EP-4524236-A2 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | Regeneron Pharmaceuticals, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-4524148-A2 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | Regeneron Pharmaceuticals, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-4524237-A2 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | Regeneron Pharmaceuticals, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-4524147-A2 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | Regeneron Pharmaceuticals, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-2510361-A2 | DETECTION OF OXIDIZED POLYPEPTIDES | Purdue Research Foundation (US) | 2012-10-17 | — | — | EP | disclosed |
| US-8143224-B2 | Oxidant resistant apolipoprotein A-1 and mimetic peptides | THE CLEVELAND CLINIC FOUNDATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110201947-A1 | OXIDIZED PARAOXONASE 1 AND PARAOXONASE 1/HDL PARTICLE NUMBER RATIO AS RISK MARKERS FOR CARDIOVASCULAR DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2011-08-18 | — | — | US | disclosed |
| WO-2011072197-A2 | DETECTION OF OXIDIZED POLYPEPTIDES | PURDUE RESEARCH FOUNDATION (US) | 2011-06-16 | — | — | WO | disclosed |
| EP-2268305-A2 | OXIDIZED PARAOXONASE 1 AND PARAOXONASE 1/HDL PARTICLE NUMBER RATIO AS RISK MARKERS FOR CARDIOVASCULAR DISEASE | The Cleveland Clinic Foundation (US) | 2011-01-05 | — | — | EP | disclosed |
| EP-2212351-A1 | OXIDANT RESISTANT APOLIPOPROTEIN A-1 AND MIMETIC PEPTIDES | The Cleveland Clinic Foundation (US) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009114875-A2 | OXIDIZED PARAOXONASE 1 AND PARAOXONASE 1/HDL PARTICLE NUMBER RATIO AS RISK MARKERS FOR CARDIOVASCULAR DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2009-09-17 | — | — | WO | disclosed |
| US-20090149390-A1 | OXIDANT RESISTANT APOLIPOPROTEIN A-1 AND MIMETIC PEPTIDES | THE CLEVELAND CLINIC FOUNDATION | 2009-06-11 | — | — | US | disclosed |
| WO-2009055538-A1 | OXIDANT RESISTANT APOLIPOPROTEIN A-1 AND MIMETIC PEPTIDES | THE CLEVELAND CLINIC FOUNDATION (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12338274-B2 | Anti-VEGF protein compositions and methods for producing the same | VEGFA, HDGF, PDGFA | SMN1; SMN2 3864/4885KDM4E 3284/4885MAPT 2868/4885 |
| US-20250197474-A1 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | VEGFA, HDGF, PDGFA | SMN1; SMN2 3864/4885KDM4E 3284/4885MAPT 2868/4885 |
| US-12319728-B2 | Anti-VEGF protein compositions and methods for producing the same | VEGFA, HDGF, PDGFA | SMN1; SMN2 3864/4885KDM4E 3284/4885MAPT 2868/4885 |
| US-20250289868-A1 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | VEGFA, HDGF, PDGFA | SMN1; SMN2 3864/4885KDM4E 3284/4885MAPT 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.